LIFE News and Press, aTyr Pharma Inc. From 09/13/21

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, investors in  aTyr Pharma  (NADSAQ: LIFE ) and LIFE stock are seeing impressive gains. At the time of writing, this clinical stage biotherapeutics company is up more than 37%. Source: luchschenF...

Gainers: Itamar Medical ITMR +45%, aTyr Pharma LIFE +35%, iRhythm Technologies (NASDAQ:IRTC) +33%, REGENXBIO RGNX +20%, Leap Therapeutics LPTX +15%. Losers: MiMedx MDXG -61%, Silverback Therapeutics (NASDAQ:SBTX) -24%, Dynavax T...

Itamar Medical (NASDAQ:ITMR) +44% on being taken over by Zoll Medical for ~$538M Leap Therapeutics (NASDAQ:LPTX) +42% to present new data from the DisTinGuish study of DKN-01 Plus Tislelizumab at the ESMO 2021 Congres BELLUS Health (NASDAQ:BLU) +24% positive interim f...

Trial met primary endpoint, ATYR1923 was safe and well-tolerated. Efficacy observed in key endpoints including steroid reduction of 58% in the 5.0 mg/kg treatment group with 33% of patients in the group able to taper completely off of steroids. Clinically meaningful ...

The reason for having a home bias is usually fear of missing information. Therefore, investors with a home bias should not invest in US-traded dark stocks, of non-reporting companies. A much better alternative is US-traded and foreign nanocaps that are filing financial reports. In thi...

aTyr Pharma, Inc. (LIFE) Q2 2021 Earnings Conference Call August 10, 2021 17:00 ET Corporate Participants Ashlee Dunston - Director, IR and Corporate Communications Sanjay Shukla - President and Chief Executive Officer Jill Broadfoot - Chief Financial Officer ConferenceCall Participants Prakh...

Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in mid-September 2021. Company to host conference call and webcast today, August 10th, at 5:00 p.m. EDT / 2:00 p.m. PDT. SAN DIEGO, Aug. 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasda...

Collaboration led by Dr. Elliott Crouser to explore underlying cellular mechanisms of pulmonary sarcoidosis and identify potential sarcoidosis biomarkers. SAN DIEGO, Aug. 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company, today a...

SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that two abstracts for the company’s lead therapeutic candidat...

SAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report second quarter 2021 financial results and provide...